CIPHER PHARMACEUTICALS INC (CPH.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:CPH - CA17253X1050 - Common Stock
13.99 CAD
-0.22 (-1.55%)
Taking everything into account, CPH scores 7 out of 10 in our fundamental rating. CPH was compared to 30 industry peers in the Pharmaceuticals industry. Both the health and profitability get an excellent rating, making CPH a very profitable company, without any liquidiy or solvency issues. CPH is evaluated to be cheap and growing strongly. This does not happen too often! These ratings could make CPH a good candidate for value and growth and quality investing.
1. Profitability
1.1 Basic Checks
In the past year CPH was profitable.
CPH had a positive operating cash flow in the past year.
In the past 5 years CPH has always been profitable.
In the past 5 years CPH always reported a positive cash flow from operatings.
1.2 Ratios
With an excellent Return On Assets value of 11.77%, CPH belongs to the best of the industry, outperforming 93.55% of the companies in the same industry.
CPH has a better Return On Equity (15.23%) than 90.32% of its industry peers.
CPH has a Return On Invested Capital of 7.23%. This is amongst the best in the industry. CPH outperforms 90.32% of its industry peers.
CPH had an Average Return On Invested Capital over the past 3 years of 8.42%. This is in line with the industry average of 8.14%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.77% | ||
| ROE | 15.23% | ||
| ROIC | 7.23% |
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
1.3 Margins
Looking at the Profit Margin, with a value of 34.68%, CPH belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
CPH's Profit Margin has improved in the last couple of years.
With an excellent Operating Margin value of 25.51%, CPH belongs to the best of the industry, outperforming 87.10% of the companies in the same industry.
In the last couple of years the Operating Margin of CPH has declined.
CPH has a better Gross Margin (74.32%) than 93.55% of its industry peers.
In the last couple of years the Gross Margin of CPH has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 25.51% | ||
| PM (TTM) | 34.68% | ||
| GM | 74.32% |
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), CPH is creating some value.
The number of shares outstanding for CPH has been increased compared to 1 year ago.
Compared to 5 years ago, CPH has less shares outstanding
The debt/assets ratio for CPH is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 6.13 indicates that CPH is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 6.13, CPH belongs to the best of the industry, outperforming 93.55% of the companies in the same industry.
The Debt to FCF ratio of CPH is 0.45, which is an excellent value as it means it would take CPH, only 0.45 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 0.45, CPH belongs to the best of the industry, outperforming 93.55% of the companies in the same industry.
A Debt/Equity ratio of 0.12 indicates that CPH is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.12, CPH is in the better half of the industry, outperforming 67.74% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | 0.45 | ||
| Altman-Z | 6.13 |
ROIC/WACC0.89
WACC8.13%
2.3 Liquidity
CPH has a Current Ratio of 1.30. This is a normal value and indicates that CPH is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of CPH (1.30) is worse than 64.52% of its industry peers.
A Quick Ratio of 0.98 indicates that CPH may have some problems paying its short term obligations.
The Quick ratio of CPH (0.98) is worse than 61.29% of its industry peers.
The current and quick ratio evaluation for CPH is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.98 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 4.76% over the past year.
Measured over the past years, CPH shows a quite strong growth in Earnings Per Share. The EPS has been growing by 12.97% on average per year.
CPH shows a strong growth in Revenue. In the last year, the Revenue has grown by 89.17%.
Measured over the past years, CPH shows a quite strong growth in Revenue. The Revenue has been growing by 8.25% on average per year.
EPS 1Y (TTM)4.76%
EPS 3Y14.06%
EPS 5Y12.97%
EPS Q2Q%2000%
Revenue 1Y (TTM)89.17%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%23.75%
3.2 Future
The Earnings Per Share is expected to grow by 20.66% on average over the next years. This is a very strong growth
CPH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 27.91% yearly.
EPS Next Y51.5%
EPS Next 2Y16.2%
EPS Next 3Y20.66%
EPS Next 5YN/A
Revenue Next Year50.96%
Revenue Next 2Y26.89%
Revenue Next 3Y27.91%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 15.37, CPH is valued correctly.
CPH's Price/Earnings ratio is rather cheap when compared to the industry. CPH is cheaper than 80.65% of the companies in the same industry.
When comparing the Price/Earnings ratio of CPH to the average of the S&P500 Index (26.56), we can say CPH is valued slightly cheaper.
CPH is valuated correctly with a Price/Forward Earnings ratio of 16.37.
77.42% of the companies in the same industry are more expensive than CPH, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of CPH to the average of the S&P500 Index (23.79), we can say CPH is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.37 | ||
| Fwd PE | 16.37 |
4.2 Price Multiples
CPH's Enterprise Value to EBITDA ratio is in line with the industry average.
Based on the Price/Free Cash Flow ratio, CPH is valued cheaply inside the industry as 83.87% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.62 | ||
| EV/EBITDA | 13.34 |
4.3 Compensation for Growth
CPH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CPH has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as CPH's earnings are expected to grow with 20.66% in the coming years.
PEG (NY)0.3
PEG (5Y)1.19
EPS Next 2Y16.2%
EPS Next 3Y20.66%
5. Dividend
5.1 Amount
CPH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX:CPH (12/12/2025, 7:00:00 PM)
13.99
-0.22 (-1.55%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners1.31%
Inst Owner ChangeN/A
Ins Owners3.62%
Ins Owner ChangeN/A
Market Cap354.93M
Revenue(TTM)50.05M
Net Income(TTM)17.36M
Analysts77.5
Price Target18.39 (31.45%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)51.24%
Min EPS beat(2)36.14%
Max EPS beat(2)66.34%
EPS beat(4)2
Avg EPS beat(4)14.52%
Min EPS beat(4)-37.21%
Max EPS beat(4)66.34%
EPS beat(8)5
Avg EPS beat(8)34.73%
EPS beat(12)9
Avg EPS beat(12)113.55%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.76%
Min Revenue beat(2)-6.01%
Max Revenue beat(2)2.48%
Revenue beat(4)1
Avg Revenue beat(4)-1.18%
Min Revenue beat(4)-6.01%
Max Revenue beat(4)2.48%
Revenue beat(8)2
Avg Revenue beat(8)-0.16%
Revenue beat(12)3
Avg Revenue beat(12)1.53%
Revenue beat(16)3
Avg Revenue beat(16)-1.19%
PT rev (1m)0.7%
PT rev (3m)2.88%
EPS NQ rev (1m)-6.06%
EPS NQ rev (3m)-6.06%
EPS NY rev (1m)9.52%
EPS NY rev (3m)-24.59%
Revenue NQ rev (1m)-6.28%
Revenue NQ rev (3m)-6.28%
Revenue NY rev (1m)-2.98%
Revenue NY rev (3m)1.24%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.37 | ||
| Fwd PE | 16.37 | ||
| P/S | 5.15 | ||
| P/FCF | 8.62 | ||
| P/OCF | 8.6 | ||
| P/B | 2.26 | ||
| P/tB | 11.29 | ||
| EV/EBITDA | 13.34 |
EPS(TTM)0.91
EY6.5%
EPS(NY)0.85
Fwd EY6.11%
FCF(TTM)1.62
FCFY11.6%
OCF(TTM)1.63
OCFY11.63%
SpS2.71
BVpS6.18
TBVpS1.24
PEG (NY)0.3
PEG (5Y)1.19
Graham Number11.25
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.77% | ||
| ROE | 15.23% | ||
| ROCE | 10.05% | ||
| ROIC | 7.23% | ||
| ROICexc | 7.75% | ||
| ROICexgc | 33.36% | ||
| OM | 25.51% | ||
| PM (TTM) | 34.68% | ||
| GM | 74.32% | ||
| FCFM | 59.76% |
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
ROICexc(3y)14.84%
ROICexc(5y)25.78%
ROICexgc(3y)32.35%
ROICexgc(5y)N/A
ROCE(3y)11.69%
ROCE(5y)20.72%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-55.02%
ROICexc growth 5Y-33.6%
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
F-Score7
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | 0.45 | ||
| Debt/EBITDA | 0.67 | ||
| Cap/Depr | 1.2% | ||
| Cap/Sales | 0.17% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 152.24% | ||
| Profit Quality | 172.34% | ||
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.98 | ||
| Altman-Z | 6.13 |
F-Score7
WACC8.13%
ROIC/WACC0.89
Cap/Depr(3y)670.82%
Cap/Depr(5y)415.05%
Cap/Sales(3y)80.33%
Cap/Sales(5y)48.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.76%
EPS 3Y14.06%
EPS 5Y12.97%
EPS Q2Q%2000%
EPS Next Y51.5%
EPS Next 2Y16.2%
EPS Next 3Y20.66%
EPS Next 5YN/A
Revenue 1Y (TTM)89.17%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%23.75%
Revenue Next Year50.96%
Revenue Next 2Y26.89%
Revenue Next 3Y27.91%
Revenue Next 5YN/A
EBIT growth 1Y29.19%
EBIT growth 3Y-15.61%
EBIT growth 5Y-7.36%
EBIT Next Year144.27%
EBIT Next 3Y50.65%
EBIT Next 5YN/A
FCF growth 1Y98.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y99.32%
OCF growth 3Y12.28%
OCF growth 5Y19.77%
CIPHER PHARMACEUTICALS INC / CPH.CA FAQ
Can you provide the ChartMill fundamental rating for CIPHER PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 7 / 10 to CPH.CA.
What is the valuation status of CIPHER PHARMACEUTICALS INC (CPH.CA) stock?
ChartMill assigns a valuation rating of 7 / 10 to CIPHER PHARMACEUTICALS INC (CPH.CA). This can be considered as Undervalued.
How profitable is CIPHER PHARMACEUTICALS INC (CPH.CA) stock?
CIPHER PHARMACEUTICALS INC (CPH.CA) has a profitability rating of 8 / 10.
How financially healthy is CIPHER PHARMACEUTICALS INC?
The financial health rating of CIPHER PHARMACEUTICALS INC (CPH.CA) is 7 / 10.